Fidelity International
NAMS icon

Fidelity International’s NewAmsterdam Pharma NAMS Stock Holding History

Fidelity International’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.35K Hold
217
– – ﹤0.01% 1135
2026
Q1 		$6.95K Buy
+217
New +$7.07K ﹤0.01% 1092

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Fidelity International's NAMS Position: Q2 2026 in Review

Fidelity International held its NewAmsterdam Pharma (NAMS) position steady in Q2 2026 at 217 shares worth $7.35K. The position accounts for ﹤0.01% of the portfolio, ranked #1135.

Fidelity International first reported a position in NAMS in Q1 2026 and has held it in 2 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Fidelity International held 217 shares of NewAmsterdam Pharma worth $7.35K as of Q2 2026.
  • Fidelity International left its NewAmsterdam Pharma share count unchanged in Q2 2026.
  • NewAmsterdam Pharma made up ﹤0.01% of Fidelity International's portfolio in Q2 2026, its #1135 holding.
  • Fidelity International first reported a position in NewAmsterdam Pharma in Q1 2026 and has held it in 2 quarters since.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Fidelity International's 13F filing for Q2 2026, filed 13 Aug 2026.